Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 52-Week Low – Here’s What Happened

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research note on Monday, October 7th. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a report on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. The firm’s fifty day moving average is $52.25 and its two-hundred day moving average is $51.88. The firm has a market cap of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The firm had revenue of $622.00 million for the quarter.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.